RT Book, Section
A1 Melvin, Cathy L.
A1 Brady, Kathleen T.
A2 Greenberg, Raymond S.
SR Print(0)
ID 1108591128
T1 Implementation Science
T2 Medical Epidemiology: Population Health and Effective Health Care, 5e
YR 2014
FD 2014
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-182272-5
LK accesspharmacy.mhmedical.com/content.aspx?aid=1108591128
RD 2024/04/25
AB Approximately  80%  of  individuals  will  become  infected  with  human  papillomavirus  (HPV)  during  their  lifetimes.  Infection  occurs  at  various  sites  in  both  sexes  and  may  result  in  anogenital  and  oropharyngeal  condyloma,  precancers,  or  cancers.  HPV  causes  more  than  750,000  cases  of  cancer  and  275,128  deaths  worldwide  per  year.  Comprehensive  cancer  screening,  diagnosis,  and  treatment  programs  have  reduced  the  incidence  of  HPV-related  cancers  where  implemented,  but  these  secondary  cancer  prevention  efforts  are  associated  with  tremendous  expense  ($8  billion/year  in  the  United  States),  complicated  logistics,  and  significant  morbidity.  HPV  vaccine  offers  an  amazing  opportunity  to  prevent  the  adverse  outcomes  associated  with  HPV  infection.  HPV  vaccine  is  a  safe,  evidence-based  intervention  to  prevent  certain  cancers  and  reduce  health  care  costs.